Not known Factual Statements About ABBV-744 preclinical studies and results
The present work examined the potential of employing ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant in addition palbociclib. ARV-825 was effective in both p53 wild-style (WT) breast tumor cells As well as in cells missing functional p53 either on your own or in combination with tamoxifen, even though the effectivenes